Tesamorelin belongs to a more specific conversation.
“Belly fat” is a broad phrase. The approved product EGRIFTA WR (tesamorelin) has a much narrower purpose.
Keep the purpose attached.
Which kind of fat, and for whom?
Tesamorelin copies a hormone signal. The pituitary responds by releasing growth hormone. That small gland sits beneath the brain. This also raises IGF-1, a growth factor.
FDA has treated tesamorelin as a biologic since March 2020.
The EGRIFTA WR (tesamorelin) label describes its approved purpose for adults who have HIV-associated lipodystrophy. This condition changes fat distribution; this product reduces the extra abdominal fat associated with it. It isn't another name for general obesity.
Weight-loss management is explicitly outside that approved purpose. In the main trials, people lost deep abdominal fat with little change in their body weight. That distinction matters if your hope is a lower number on the scale.
A separate small JAMA trial in adults with HIV found reductions in visceral fat and liver fat. Visceral fat sits around internal organs. Treating fatty liver is not an FDA-approved use of tesamorelin.
We'd keep those limits beside the result. A finding can be worthwhile without applying to everyone who describes their goal as losing belly fat.
There's a longer-term question too. In the trials summarized in the label, visceral fat returned after a switch to placebo. That makes follow-up part of the discussion from the outset.
The checks are part of the choice
The label describes raised blood sugar, fluid retention, joint pain and injection-site reactions. It calls for checking blood sugar and monitoring IGF-1.
It also rules out use with active cancer, pregnancy and certain pituitary problems. These are reasons for a clinician to know someone's medical history, even when a study result looks appealing.
We'd want to understand what those checks involve before treating a fat measurement as the whole story.
A useful question is who will review those results with you. Follow-up deserves a clear explanation too.
Approval belongs to the product and purpose
Using an approved medicine for another purpose is called off-label use. It doesn't mean that other purpose has FDA approval.
Compounded preparations have a separate status: they are not FDA-approved. An approved product's label doesn't transfer its approval to them.
A narrower answer can be useful
Our comparison keeps internal abdominal fat separate from body weight. That's a practical distinction to take into a clinical conversation.
Some doctors and compounding pharmacies prescribe compounded tesamorelin, with Promise Peptides (mypromise.com) as one route.